搜索到 1000 条关于 과천경마장 입장료 Q111.top 부산경마 온라인 경마 시행 경마 온라인 배팅방법 Azi 的文章

2022.05.01 2022,博士们,又开始晒工资了

AP。年薪10万。H:坐标新加坡。坡村top2高校之一。tenure track AP。年薪总共约70万人民币。—&mdash...40,现在一心想找个20左右的教职,啊……好难。——2022-04-25@匿名用户沪上top2毕业,农学天坑
七夕节:话一话古代十大奇葩避孕方式

2016.08.09 七夕节:话一话古代十大奇葩避孕方式

CRACKED 网站为大家来盘点了历史上奇葩十大避孕措施,看完之后你会觉得没有什么不可能,妇产君反正已经看到下颌脱臼了。Top 10 黄鼠狼睾丸欧洲正处于「黑暗时代」时期...吧。Top 9 鳄鱼便便创造出了金字塔、木乃伊的古埃及人,在避孕这件事上可以说是煞费苦心,想法也算得上简单粗暴。想要避免怀孕?只要用一些东西堵住不让精子进入
6 个问题全面解析:肉毒素瘦脸

2017.08.01 6 个问题全面解析:肉毒素瘦脸

)I123II111-2III222-3IV333V--3问题五:注射效果怎么评价?答:为了评价肉毒素治疗效果,可引入一个统一的计算公式(图 7):图 7(a)注射前,(b)注射后第 n 个月; A 或 A&#39..., Herrler T, Li Q. Classification of masseter hypertrophy for tailored botulinum
2013年国际及国内顶级生物类学术期刊盘点

2013.06.27 2013年国际及国内顶级生物类学术期刊盘点

Q REV BIOPHYS11.875...10.353111GENOME BIOL
原药出口放缓 小专品种强势

2012.12.03 原药出口放缓 小专品种强势

类药物35.1%、泌尿系统类药物8.1%、心血管系统类药物7.1%。其中,对出口拉动较大的小品类包括茄红素、小品种激素、辅酶Q10,仿制药和中间体则包括沙坦类...方面,2012年1~8月,进口类药品总额111亿美元,同比增长近20%;进口原料药类商品45亿美元,占进口医药类商品的44%。其中,化学原料药进口额25亿美元;生化

2012.09.19 2011年生物仿制药会议(Biosimilars Asia 2011)

时间: 2011-5-23 至 2011-5-26
地点:Grand Hyatt Shanghai
主办单位: IBC Asia (S) Pte Ltd

会议简介

According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.

Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..

IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.

5 Reasons To Attend
  • Only conference in Asia which addresses concerns faced by the Asian biosimilar companies with experts from the region and beyond
  • Learn from and personally meet senior executives from the major stakeholders amongst from biosimilar to innovator companies
  • The most comprehensive event highlighting key challenges in the industry including manufacturing, marketing, pricing, transitioning from generics to biosimilars and regulatory issues
  • Showcasing unique case studies from leading Asian and international biosimilar companies
  • Gather the latest insights from regional biosimilar companies and MNCs about their strategic decisions and how they are positioning themselves for success

Industry Gurus / Speakers
Biocon, Pfizer, Genentech, Roche, Teva, Hospira, Sandoz, Momenta, Intas, Dr Reddy’s, Shenzhen Main Luck Pharmaceuticals

Past Attendees Include
Vice President, ASTRAZENECA INNOVATION CENTER (China)
Senior Director, GENENTECH INC, (USA)
Managing Director, BECTON DICKINSON CO (BD BIOSCIENCES) (Singapore)
Managing Director, ASAHI GLASS CO LTD (Japan)
Deputy General Manager, SINOPHARM (China)
Head, Biotech Research, USV LTD (India)
General Manager, JCR PHARMACEUTICALS CO LTD (Japan)
Vice President, R&D/Business Development, MAIN LUCK PHARMACEUTICALS INC (China)
Senior Research Associate, HANWHA CHEMICAL (South Korea)
Vice President, BOEHRINGER INGELHEIM GMBH (Germany)
General Manager, GLAXOSMITHKLINE (CHINA) INVESTMENT CO LTD (China)
IP Director, HOSPIRA (AUSTRALIA)
President, MYCENAX BIOTECH INC (Taiwan)
Senior Director, MERCK & CO INC (USA)
Associate Director, DR REDDY''''''''S LABORATORIES LTD (India)
Chairman, SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO LTD (SCIPROGEN) (China)COO, SHANGHAI CELGEN BIOPHARMACEUTICALS (China)
Chief Representative, TTY BIOPHARM CO LTD (Taiwan)COO, 3SBIO (China)
Project Director, JIANGSU CHIA TAI TIANQING PHARMACEUTICAL CO LTD (China)Associate Director, PFIZER INVESTMENT CO LTD (China)
General Manager, NIPPON KAYAKU CO LTD (Japan)
President, HENLIUS BIOPHARMACEUTICALS INC & SHANGHAI HENLIUS BIOTECH (USA)
Vice President, RANBAXY (USA)

Registration

FEES per delegate
Early Bird Rate
Register & Pay before 11 March 2011
Special Rate
Register & Pay before 15 April 2011
Normal Rate
Register & Pay after 15 April 2011
Group Rate
Group of 3 or more
?
US$ / CNY
US$ / CNY
US$ / CNY
US$ / CNY
4 day package
(Conf + Pre & Post Workshops)
2,495 /
16,600
2,695 /
17,950
2,895 /
19,500
2,175 /
14,650
3.5 day package (Conf + Workshop C & A or B )

2,295 /
15,500

2,495 /
16,600
2,695 /
17,950
2,025 /
13,500
3 day package (Conf + Workshop A & B or C)
1,995 /
13,500
2,195 /
14,600
2,395 /
15,950

1,795 /
12,000

2.5 day package (Conf + Workshop A or B)
1,795 /
12,000
1,995 /
13,500
2,195 /
14,600
1,695 /
10,950
2 day package
(Conf only)
1,495 /
9,950
1,695 /
11,300
1,895 /
12,600
1,495 /
9,950

Register Now

PAYMENT TERMS

Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.

Payments by Singapore Dollars (S$)

  • Payments by S$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” payable in Singapore.
  • Payment by telegraphic transfer in S$ must be made to:
    IBC Asia (S) Pte Ltd
    A/C No.: 147-059513-001 (SGD)
    The Hongkong and Shanghai Banking Corporation Limited
    21 Collyer Quay, HSBC Building, Singapore 049320
    Bank Swift Code: HSBCSGSG
    Bank Code: 7232
  • Payment by Credit Card (AMEX, VISA or MASTERCARD). Please provide your Card Number, Name of Cardholder, Expiry Date and your Signature and send it by fax to +65 6508 2407.
Payments by RMB (CNY)
  • Payment by telegraphic transfer in CNY must be made to:
    A/C Name:
    A/C No.: 720-031103-001
    Beneficiary Bank:
    Bank Address: No. 1000 Lujiazui Rind Road,
    Pudong, Shanghai 200120, P.R. China
    Bank Swift Code: HSBCCNSH
CANCELLATIONS SUBSTITUTION
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.

Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.


DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.
联系方式电话:+65 650 82401

2012.09.19 2010 第五届国际基因组学大会(ICG-V)

, please click: http://www.genomeconference.org/pages/Abstract.aspxTop Poster

2019.02.20 2019 全国食品行业质量管理与技术论坛

;13693666225 微信:13693666225QQ: 1824643339 网址
复杂病变:右肺枯成了「蜂窝煤」

2018.05.09 复杂病变:右肺枯成了「蜂窝煤」

患者信息:女,73 岁。主诉::咳嗽、咳痰、胸闷、气喘,一月余,加重 3 天。现病史:患者既往肺结核病史 40 余年,经抗痨抗感染治疗后好转出院,近 40 年未复发。一月前在无明显诱因下出现咳嗽咳痰,呈白色黏液痰,伴胸闷气喘无心慌,无恶心呕吐,无腹泻腹痛,无抽搐及意识障碍等症状。体格检查:T:38.7℃,P:111
送书啦!儿科专业讨论版发帖赢奖品啦~

2017.11.02 送书啦!儿科专业讨论版发帖赢奖品啦~

@yzf111 @文侠@wsshihan 
谁将是2020年全球前十大心血管医疗器械公司

2014.11.10 谁将是2020年全球前十大心血管医疗器械公司

根据EvaluateMedTech的一份研究报告表明,美敦力将在未来6年,继续引领心血管领域的市场。美敦力预计在2020年的全球销售额将达到111亿美金,将与第二大公司圣犹达医疗保持大幅的差距。而排在前五位的公司将会还有波士顿科学,雅培和爱德华。这份报告并没有考虑美敦力将会并购柯惠医疗的事宜,而这

2012.09.19 2012 中国医疗器械高峰论坛

trials and regulatory affairs
A special showcase of top 10 Chinese innovative device companies and top 5 selected US/EU device companies interested in China

2020.06.17 【直播 | 现场】计算机辅助设计—分子模拟与蛋白互作研讨班(8.20-22)

。【报名回执】访问此链接填写报名回执(https://www.wjx.top/jq/80710449.aspx)【咨询请联系】QQ 号:2814500767邮箱
High performance plasma amyloid-β biomarkers for Alzheimer’s disease

2019.05.28 High performance plasma amyloid-β biomarkers for Alzheimer’s disease

data set (Australia,n = 252 including 111 individuals diagnosed using&nbsp... and validation, 94.1%,n = 111) with an accuracy approximately equal to 90% when
2015AAOS:全髋置换可作为髋部骨折治疗失败的补救措施

2015.03.25 2015AAOS:全髋置换可作为髋部骨折治疗失败的补救措施

以及功能结果。将股骨颈骨折(n=111)和转子间骨折(n=191)分组,进行相关并发症的亚组分析。使用T检验进行统计学分析。常见需进行补救性治疗的原因为早期固定...THA治疗后的并发症包括19例(9.9%)术中和术后再次骨折,7例(3.7%)脱位,2例(1.05%)感染。111例股骨颈骨折补救性THA治疗后的并发症包括6例
荟萃分析揭示与结肠癌发病相关的遗传位点

2012.10.23 荟萃分析揭示与结肠癌发病相关的遗传位点

错误发现概率测试进行评估.研究者认为在13个基因位点有16个独立变量,包括MUTYH, MTHFR, SMAD7以及常见的标记位点如8q24, 8q23.3, 11q23.1, 14q22.2, 1q41, 20p12.3, 20q13.33, 3q26.2, 16q22.1, and 19q13.1,上述
上一页 1 2 3 ... 48 49 50 下一页 到第